• Home
  • Uncategorized
  • Cardiac Biomarkers to Refine Pre-Test Probability for Coronary Obstruction and Predict Survival after Revascularisation in Chronic Coronary Syndrome

Cardiac Biomarkers to Refine Pre-Test Probability for Coronary Obstruction and Predict Survival after Revascularisation in Chronic Coronary Syndrome

Background and aims The utility of cardiovascular and inflammatory biomarkers to detect coronary obstruction and predict survival benefit of revascularisation in chronic coronary syndrome (CCS) remains unclear. Methods Patients undergoing coronary angiography for suspected CCS were studied. High-sensitivity cardiac troponin T (hsTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and copeptin were measured. Diagnostic performance to detect anatomical coronary stenosis (i.e. [≥]50%) was assessed using Receiver Operating Characteristic (ROC) analysis with Net Reclassification Improvement (NRI). Survival analysis using multivariate Cox regression assessed treatment-stratified biomarker performance and biomarker x treatment interaction. Results Among 2,251 patients, 888 (39.4%) had coronary obstruction. Only hsTnT provided meaningful diagnostic capacity (Area Under the Curve; AUC 0.669), comparable with risk factor-weighted clinical likelihood (RF-CL) estimate recommended by the current guidelines (AUC 0.663). Reclassification value demonstrated an inverse relationship to RF-CL: very low (NRI=38.4%), low (NRI=19.3%), and intermediate/high likelihood (NRI=12.4%). NT-proBNP was the strongest universal mortality predictor across all treatment categories: Optimal Medical Therapy (OMT; HR 1.488, 95%CI:1.288-1.720, p<0.001), Percutaneous Coronary Intervention (PCI; HR 1.220, 95%CI:1.020-1.458, p=0.029), Coronary Artery Bypass Grafting (CABG; HR 1.220, 95%CI:1.049-1.420, p=0.010). Interaction analysis (p=0.024) demonstrated that in patients with NT-proBNP <150 pg/mL the revascularisation group has an improved survival (HR 0.64, 95%CI:0.47-0.87, p=0.005), whilst this was not observed for the patients with NT-proBNP ?150 pg/mL (HR 0.96, 95%CI:0.71-1.30, p=0.782). Conclusions HsTnT provides meaningful diagnostic value with RF-CL category-specific incremental benefit following an inverse gradient pattern. The NT-proBNP 150 pg/mL threshold identifies patients with improved survival after revascularisation.

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844